DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Arzoxifene
Arzoxifene
The Mechanisms and Managements of Hormone-Therapy Resistance in Breast and Prostate Cancers
In Vitro and in Silico Analyses of the Inhibition of Human Aldehyde Oxidase By
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S
WO 2009/137104 Al
(12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub
Breast-Cancer-Medications Surveillance
Design and Synthesis of Selective Estrogen Receptor Β Agonists and Their Hp Armacology K
Once-Promising Arzoxifene Flunks Phase III Trial
Raloxifene Or Calcitonin
022247Orig1s000
Stembook 2018.Pdf
Osteoporosis Therapy Pipeline Is Chock Full
(12) Patent Application Publication (10) Pub. No.: US 2015/0284357 A1 Thatcher Et Al
Viktoria Behse Aus Münster
On Human Endometrial Cancer Growth in Athymic Mice1
Appendix A: Mammalian Studies Describing the Effects of Chemicals
MINI-REVIEW Sequence to Structure Approach Of
Endometrial Effects of Serms Santiago Palacios
Top View
2418.Full-Text.Pdf
Future Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors I
Raloxifene for the Treatment of Postmenopausal Osteoporosis
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
5403.Full-Text.Pdf
(12) United States Patent (10) Patent No.: US 9,475,791 B2 Thatcher Et Al
Supplementary Materials to the Paper a COVID-19 Drug Repurposing
Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density
Customs Tariff - Schedule Xxi - 1
Safety of Vaginal Estrogens: a Systematic Review Supplemental
Endocrine Treatment and Prevention of Breast and Gynaecological Cancers
Osteoporosis Osteoporosis Diagnosis and Management
Estrogen Receptor/ERR
203505Orig1s000
Chemoprevention of Breast Cancer: the Paradox of Evidence Versus Advocacy Inaction
The Discovery and Development of Selective Estrogen Receptor Modulators (Serms) for Clinical Practice
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
― D06 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版( 2019) カテゴリー別リスト
The Role of Menopausal Hormone Therapy And
Classification of Anti-Estrogens According to Intramolecular FRET Effects on Phospho-Mutants of Estrogen Receptor A
Treatment of Hot Flushes, Vasomotor Symptoms, and Night Sweats with Sex Steroid Precursors in Combination with Selective Estrogen Receptor Modulators
Design, Synthesis and Biological Screening of Focused Libraries of New Antiestrogens
Raloxifene Hcl) in Increasing BMD in Postmenopausal Women with Osteoporosis
UWHC IV Infusion Mini Manual
(12) Patent Application Publication (10) Pub. No.: US 2017/0056347 A1 Glick Et Al
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S
Estrogens and SERMS As Adjunctive Treatments for Schizophrenia
Customs Tariff - Schedule
Substance Class No. of Class Anabolic Androgen Steroids 1. Growth
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
MINI-REVIEW Sequence to Structure Approach Of
The Role of Estrogen Receptors and Their Signaling Across Psychiatric Disorders
(12) Patent Application Publication (10) Pub. No.: US 2004/0142914 A1 Friedman Et Al
Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer
Are Nonmonotonic Dose Response Curves (Nmdrcs) Common After Estrogen Or Androgen Signaling Pathway Disruption
L:\0900\0900PHARMAPPX .Wpd
Arzoxifene: a Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer Commentary Re C
Management of Osteoporosis in Postmenopausal Women: 2006 Position Statement of the North American Menopause Society
Raloxifene As Treatment for Various Types of Brain Injuries and Neurodegenerative Diseases: † a Good Start